Klaria Pharma Holding ABFRA:6FN -8.28%28 Current Ratio is 0.06 as of Mar. 2026, which is 94% below its 10-year median of 0.93. GuruFocus rates FRA:6FN with a GF Score™ of 28/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 995 Drug Manufacturers companies, Klaria Pharma Holding AB ranks worse than 98.19% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Klaria Pharma Holding AB's current ratio for the quarter that ended in Mar. 2026 was 0.06.
Klaria Pharma Holding AB has a current ratio of 0.06. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Klaria Pharma Holding AB has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Klaria Pharma Holding AB's Current Ratio or its related term are showing as below:
FRA:6FN'
s Current Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.93 Max: 20.79
Current: 0.06
During the past 12 years, Klaria Pharma Holding AB's highest Current Ratio was 20.79. The lowest was 0.05. And the median was 0.93.
FRA:6FN's Current Ratio is ranked worse than 98.19% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs FRA:6FN: 0.06
Klaria Pharma Holding AB (FRA:6FN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Klaria Pharma Holding AB Current Ratio Related Terms
Klaria Pharma Holding AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klaria Pharma Holding AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Klaria Pharma Holding AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Klaria Pharma Holding AB (FRA:6FN) has a Current Ratio of 0.06 as of Mar. 2026. This is 94% below median its historical median of 0.93. Over the past decade, Klaria Pharma Holding AB's Current Ratio has ranged from 0.05 to 20.79. According to the industry distribution chart, Klaria Pharma Holding AB ranks #977 out of 995 companies in the Drug Manufacturers industry, placing it in the top 98.2%.
Is Klaria Pharma Holding AB's Current Ratio too high?
Klaria Pharma Holding AB's current Current Ratio of 0.06 is 94% below median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 20.79. The Drug Manufacturers industry median Current Ratio is 2.00. Klaria Pharma Holding AB's value of 0.06 is 97% below this industry median. Based on the distribution chart, Klaria Pharma Holding AB ranks #977 out of 995 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Klaria Pharma Holding AB ranks #977 out of 995 companies for Current Ratio. This places Klaria Pharma Holding AB in the lower half of its industry. The industry median Current Ratio is 2.00. Klaria Pharma Holding AB's value of 0.06 is 97% below this benchmark. Historically, Klaria Pharma Holding AB's own Current Ratio has ranged from 0.05 to 20.79 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 2.00, Klaria Pharma Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Klaria Pharma Holding AB's current Current Ratio of 0.06 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current Current Ratio is 0.06, which is 94% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 99.3% above its estimated fair value. The current Current Ratio is 0.06, which is 94% below median its 10-year median of 0.93 and 97% below the Drug Manufacturers industry median of 2.00. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current Current Ratio is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of €0.06 is trading 99.3% above its estimated GF Value™ of €0.03.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:6FN:
Current Ratio: 0.06 (94% below median its 10-year median of 0.93)
GF Value™: €0.03 vs. price of €0.06 (99.3% above fair value)
Industry Position: 97% below the Drug Manufacturers median (#977 of 995)
No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score
Get the complete analysis for FRA:6FN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FN has been successfully added to your 
